Groundbreaking Clinical Trials for Universal Artificial Blood
Researchers at NARA Medical University in Kashikara, Japan, have embarked on what many are calling “groundbreaking” clinical trials focusing on the development of universal artificial blood.
This synthetic blood could potentially transform the medical field by addressing a pressing issue: the significant shortage of blood for patients worldwide. It’s a challenge that, as you might guess, affects countless lives.
However, it’s worth noting that this isn’t the first venture into artificial blood. Professor Hiromi Sakai leads this study, which is part of ongoing efforts to tackle global blood supply shortages. Similar research has been conducted in both the US and the UK.
The artificial blood contains red blood cells and platelets and is produced by extracting hemoglobin—an oxygen-carrying molecule—from the blood of expired donors. It’s a fascinating process that aims to replicate the function of natural blood.
According to reports, hemoglobin imitates natural red blood cells and addresses many issues linked with traditional transfusions that can carry viruses.
In a recent clinical trial at NARA Medical University, 100 to 400 milliliters of this synthetic blood were given to 16 healthy adult volunteers. I mean, that’s quite a significant step forward, really.
A source stated, “The launch of a new clinical trial in Japan using artificial blood products derived from human hemoglobin represents a potentially exciting step in transfusion medicine. Despite being promising, this field has encountered notable challenges around safety, stability, and oxygen delivery effectiveness.”
There’s an important emphasis here: “This test needs to prove that artificial blood is safe for humans. It must perform as effectively as donor blood in various clinical situations. Artificial blood has its advantages, like, well, no compatibility worries.”
Yet, there’s a catch. Because the artificial blood employs hemoglobin sourced from human donors, it shares the same infection risk concerns as regular blood does. But researchers believe that, similar to regular donor blood, rigorous testing can mitigate these risks.
Another interesting aspect is that this synthetic blood boasts a shelf life of over a year at room temperature. This quality makes it potentially vital during emergencies—think war zones or natural disasters.
Currently, researchers are seeking approval from the Japanese Ministry of Health to move towards mass adoption of this universal artificial blood, meaning more trials are likely on the horizon.
